Featured Studies

Gigantism is a condition characterized by excessive growth and height significantly above average, caused by over-production of growth hormone (GH) during childhood. Investigators at the National Institutes of Health (NIH) want to see if a drug that antagonizes growth hormone action, called pegvisomant, can help children and adolescents with gigantism.

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.

Join a National Institutes of Health (NIH) research study seeking mean men who have a genetic risk factor for developing prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.

National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.

Doctors at the National Institutes of Health (NIH) seek healthy volunteers (with or without a sickle cell trait) and patients with sickle cell for a research study. Sickle cell disease is a genetic blood disorder that occurs mainly in people of African descent. Study participants will have a one-time visit to the NIH to provide blood samples. Researchers hope this study will help us better understand sickle cell disease.

Researchers at the National Institutes of Health (NIH) are studying if the medication danazol can be used to treat people with short telomere disease who also have bone marrow failure, liver, or lung disease. In recent studies, danazol, at high doses, showed a positive influence on telomere length. Additional research is needed to learn more about the role of different doses of danazol on telomere disease as well as its effects on secondary diseases.

Researchers at the National Institutes of Health are conducting a research study to learn more about the motor skill and brain development of infants who are at high-risk for or diagnosed with Cerebral Palsy (CP) and Autism Spectrum Disorder (ASD) compared to infants with typical development. The results of this study may assist with better methods for early diagnosis as well as improved treatment for children with CP and ASD. The results of this study may eventually assist with better methods for early diagnosis as well as improved treatment for children with autism.

Crohn's disease is a chronic bowel illness that is a lifelong condition characterized by relapsing inflammation. Although there is no cure for Crohn's disease, researchers at the National Institutes of Health (NIH) are investigating if Vorinostat is safe for people with Crohn's Disease. Participants will receive maintenance therapy with Stelara® after successful treatment with Vorinostat.